Evaluation of Resistance Development to the Gwt1 Inhibitor Manogepix (APX001A) in Species.

Manogepix (MGX) targets the conserved fungal Gwt1 enzyme required for acylation of inositol early in the glycosylphosphatidylinositol biosynthesis pathway. The prodrug fosmanogepix is currently in clinical development for the treatment of invasive fungal infections. We determined that the median frequencies of spontaneous mutations conferring reduced susceptibility to MGX in , , and ranged from 3 × 10 to <1.85 × 10 Serial passage on agar identified mutants of and with reduced susceptibility to MGX; however, this methodology did not result in mutants with reduced susceptibility. Similarly, serial passage in broth resulted in ≤2-fold changes in population MIC values for , , and A spontaneous V163A mutation in the Gwt1 protein of and a corresponding heterozygous V162A mutant were obtained. A V163A Gwt1 mutant generated using CRISPR, along with V162A and V168A mutants expressed in and Gwt1, respectively, all demonstrated reduced susceptibility to MGX versus control strains, suggesting the importance of this valine residue to MGX binding across different species. Cross-resistance to the three major classes of antifungals was evaluated, but no changes in susceptibility to amphotericin B or caspofungin were observed in any mutant. No change was observed in fluconazole susceptibility, with the exception of a single non-Gwt1 mutant, where a 4-fold increase in the fluconazole MIC was observed. MGX demonstrated a relatively low potential for resistance development, consistent with other approved antifungal agents and those in clinical development.